Companies Dominating the Histamine Toxicity Landscape
- Johnson and Johnson company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mylan Laboratories Ltd
- Neogen Corporation
- Pfizer Inc
- Travere Therapeutics, Inc.
- Alembic pharmaceuticals
- Intas Pharmaceuticals Ltd
- Sanofi Aventis Ltd
- Cipla Limited
- Actavis Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Two new tests to detect Histamine have been launched by Neogen, Reveal for histamine and Reveal Q+ for histamine. Reveal and Reveal Q+ assays are easy to use lateral flow tests using a simple water extraction method, providing results in a matter of minutes and eliminating the need to dispose of any chemicals, as is required by other commercially available histamine detection methods, which reduce the time needed to test.
- Travere Therapeutics, Inc. reported that the US Food and Drug Administration granted accelerated approval for FILSPARRI to reduce proteinuria in adults with primary IgAN who are at risk of rapid disease progression, typically with a urine protein-to-creatinine ratio ≥1.5 g/g. This indication is given with accelerated approval based on reduction of proteinuria. It has not been established whether FILSPARI slows the decline in renal function in patients with IgAN. Continued approval of FILSPARI may require confirmation of clinical benefit in the ongoing Phase 3 PROTECT study, which is designed to show whether FILSPARI slows the decline in kidney function. Peak results from the two-year confirmatory endpoint of the PROTECT study are expected in the fourth quarter of 2023 and are intended to support traditional FILSPAR approval.
